神经系统疾病及相关治疗药物对骨质疏松症影响的研究进展

doi:10.12114/j.issn.1007-9572.2024.0198

中国全科医学 ›› 2025, Vol. 28 ›› Issue (17): 2092-2100.DOI: 10.12114/j.issn.1007-9572.2024.0198

• 专题笔谈·继发性骨质疏松症 • 上一篇下一篇

神经系统疾病及相关治疗药物对骨质疏松症影响的研究进展

谭文彬¹^,², 李佳¹^,²^,³^,^*(), 刘明玉¹^,², 路永欣¹^,², 程雅欣¹

¹510010　广东省广州市，中国人民解放军南部战区总医院内分泌科
²510515　广东省广州市，南方医科大学第一临床医学院
³510006　广东省广州市，广东药科大学研究生院

收稿日期:2024-06-10 修回日期:2024-08-20 出版日期:2025-06-15 发布日期:2025-04-22
通讯作者: 李佳
作者贡献：
谭文彬负责论文的构思与起草；李佳指导论文的修订和质量控制，对论文整体负责；刘明玉、路永欣、程雅欣负责指导论文修订。
基金资助:
国家重点研发计划(2021YFC2501701); 广东省中央引导地方科技发展专项基金(KTP20190249)

Research Progress on the Influence of Nervous System Diseases and Related Therapeutic Drugs on Osteoporosis

TAN Wenbin¹^,², LI Jia¹^,²^,³^,^*(), LIU Mingyu¹^,², LU Yongxin¹^,², CHENG Yaxin¹

¹Department of Endocrinology, General Hospital of Southern Theater Command of the People's Liberation Army, Guangzhou 510010, China
²The First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China
³Graduate School of Guangdong Pharmaceutical University, Guangzhou 510006, China

Received:2024-06-10 Revised:2024-08-20 Published:2025-06-15 Online:2025-04-22
Contact: LI Jia

分享到

摘要/Abstract

摘要： 骨质疏松症（OP）患者常共患多种疾病，除了年龄、性别、种族等一般致OP危险因素外，共患疾病及其相关治疗均可对骨代谢产生影响。目前关于神经系统疾病合并OP相关研究较为缺乏，本文拟从流行病学特征、骨量流失特点、相关发病机制及诊疗进展4个方面进行综述，以期为神经系统疾病患者骨损害机制、OP预防及抗骨质疏松治疗等提供参考。

关键词: 骨质疏松, 继发性骨质疏松症, 脑卒中, 脊髓损伤, 多发性硬化, 帕金森病, 阿尔茨海默病, 癫痫, 治疗, 综述

Abstract:

Patients with osteoporosis (OP) often suffer from a variety of diseases. In addition to general risk factors such as age, gender, race, comorbidities and related treatments can affect bone metabolism. At present, there are relatively few studies on the association between neurological disorders and OP. Therefore, this article intends to review the epidemiological characteristics, bone loss feature, related pathogenesis and progress of diagnosis and treatment, in order to provide reference for the mechanism of bone damage, OP prevention and anti-osteoporosis treatment in patients with nervous system diseases.

Key words: Osteoporosis, Secondary osteoporosis, Stroke, Spinal cord injury, Multiple sclerosis, Parkinson's disease, Alzheimer's disease, Epilepsy, Treatment, Review

中图分类号:

R 681

谭文彬,李佳,刘明玉,等. 神经系统疾病及相关治疗药物对骨质疏松症影响的研究进展[J]. 中国全科医学, 2025, 28(17): 2092-2100. DOI: 10.12114/j.issn.1007-9572.2024.0198.
TAN Wenbin,LI Jia,LIU Mingyu, et al. Research Progress on the Influence of Nervous System Diseases and Related Therapeutic Drugs on Osteoporosis[J]. Chinese General Practice, 2025, 28(17): 2092-2100. DOI: 10.12114/j.issn.1007-9572.2024.0198.

参考文献 85

[25]	BELLOMO G, SANTAMBROGIO L, FIACCONI M, et al. Plasma profiles of adrenocorticotropic hormone，cortisol，growth hormone and prolactin in patients with untreated Parkinson's disease[J]. J Neurol，1991，238(1)：19-22. DOI：10.1007/BF00319704.
[26]	HASUIKE Y, ENDO T, KOROYASU M, et al. Bile acid abnormality induced by intestinal dysbiosis might explain lipid metabolism in Parkinson's disease[J]. Med Hypotheses，2020，134：109436. DOI：10.1016/j.mehy.2019.109436.
[27]	胡洁云，邬思繁，楼晓霞，等. PINP、β-CTx与帕金森病患者骨质疏松的关系研究[C]//2018年浙江省医学会骨质疏松与骨矿盐疾病分会学术年会暨骨质疏松症和骨质疏松性骨折诊治进展专题研讨会. 嘉兴：[出版者不详]，2018.
[28]	OZTURK E A, GUNDOGDU I, TONUK B, et al. Bone mineral density and serum vitamin D status in Parkinson's disease：are the stage and clinical features of the disease important?[J]. Neurol India，2020，68(2)：394-400. DOI：10.4103/0028-3886.283755.
[29]	ALI S J, ELLUR G, KHAN M T, et al. Bone loss in MPTP mouse model of Parkinson's disease is triggered by decreased osteoblastogenesis and increased osteoclastogenesis[J]. Toxicol Appl Pharmacol，2019，363：154-163. DOI：10.1016/j.taap.2018.12.003.
[30]	BOELENS KEUN J T, ARNOLDUSSEN I A, VRIEND C, et al. Dietary approaches to improve efficacy and control side effects of levodopa therapy in Parkinson's disease：a systematic review[J]. Adv Nutr，2021，12(6)：2265-2287. DOI：10.1093/advances/nmab060.
[31]	施静静，刘毅，陈涛，等. 阿仑膦酸钠联合钙尔奇D预防帕金森患者骨质疏松及髂骨骨折的疗效观察[J]. 现代医院，2015，15(12)：59-61. DOI：10.3969/j.issn.1671-332X.2015.12.018.
[32]	TANNER C M, CUMMINGS S R, SCHWARZSCHILD M A, et al. The TOPAZ study：a home-based trial of zoledronic acid to prevent fractures in neurodegenerative Parkinsonism[J]. NPJ Parkinsons Dis，2021，7(1)：16. DOI：10.1038/s41531-021-00162-1.
[33]	AZADVARI M, MIRMOSAYYEB O, HOSSEINI M, et al. The prevalence of osteoporosis/osteopenia in patients with multiple sclerosis（MS）：a systematic review and meta-analysis[J]. Neurol Sci，2022，43(6)：3879-3892. DOI：10.1007/s10072-022-05871-w.
[34]	ROSS B J, ROSS A J, LEE O C, et al. Osteoporosis management and secondary fragility fracture rates in patients with multiple sclerosis：a matched cohort study[J]. Osteoporos Int，2022，33(9)：1999-2010. DOI：10.1007/s00198-022-06451-6.
[1]	HUDEC S M, CAMACHO P M. Secondary causes of osteoporosis[J]. Endocr Pract，2013，19(1)：120-128. DOI：10.4158/EP12059.RA.
[2]	MAHITTHIHARN K, KOVINDHA A, KAEWCHUR T, et al. Prevalence and influencing factors of spinal cord injury-related osteoporosis and fragility fractures in Thai people with chronic spinal cord injury：a cross-sectional，observational study[J]. J Spinal Cord Med，2023，46(3)：458-465. DOI：10.1080/10790268.2022.2054763.
[3]	常四鹏，王炎强，耿德勤，等. 颅内动脉粥样硬化性狭窄致首发缺血性脑卒中老年患者并发骨质疏松的危险因素分析[J]. 实用医学杂志，2018，34(6)：890-892，896. DOI：10.3969/j.issn.1006-5725.2018.06.004.
[4]	KAPRAL M K, FANG J M, ALIBHAI S M, et al. Risk of fractures after stroke：results from the Ontario stroke registry[J]. Neurology，2017，88(1)：57-64. DOI：10.1212/WNL.0000000000003457.
[5]	LIU R Q, CHAO A J, WANG K, et al. Incidence and risk factors of medical complications and direct medical costs after osteoporotic fracture among patients in China[J]. Arch Osteoporos，2018，13(1)：12. DOI：10.1007/s11657-018-0429-5.
[6]	ROLVIEN T, AMLING M. Disuse osteoporosis：clinical and mechanistic insights[J]. Calcif Tissue Int，2022，110(5)：592-604. DOI：10.1007/s00223-021-00836-1.
[7]	何静杰，张蕴忱，崔利华，等. 脑卒中偏瘫患者继发骨质疏松症的特点[J]. 中国临床康复，2005，9(25)：214-215. DOI：10.3321/j.issn:1673-8225.2005.25.004.
[8]	UTOR T W, KURA J, MATTINGLY A J, et al. The effects of exercise and activity-based physical therapy on bone after spinal cord injury[J]. Int J Mol Sci，2022，23(2). DOI：10.3390/ijms23020608.
[9]	ABDELRAHMAN S, IRELAND A, WINTER E M, et al. Osteoporosis after spinal cord injury：aetiology，effects and therapeutic approaches[J]. J Musculoskelet Neuronal Interact，2021，21(1)：26-50.
[10]	张盘德，冯彦林，范小艳，等. 脑卒中偏瘫患者骨密度变化及继发骨质疏松症的特点[J]. 中国康复医学杂志，2008，23(9)：789-791. DOI：10.3969/j.issn.1001-1242.2008.09.011.
[11]	QIAO X C, ZHANG K, LI X Y, et al. Gut microbiota and fecal metabolic signatures in rat models of disuse-induced osteoporosis[J]. Front Cell Infect Microbiol，2022，12：1018897. DOI：10.3389/fcimb.2022.1018897.
[35]	VOGLER M, OLEKSY A, SCHULZE S, et al. An antagonistic monoclonal anti-Plexin-B1 antibody exerts therapeutic effects in mouse models of postmenopausal osteoporosis and multiple sclerosis[J]. J Biol Chem，2022，298(9)：102265. DOI：10.1016/j.jbc.2022.102265.
[36]	SOBH M M, ABDALBARY M, ELNAGAR S, et al. Secondary osteoporosis and metabolic bone diseases[J]. J Clin Med，2022，11(9)：2382. DOI：10.3390/jcm11092382.
[37]	KAMPMAN M T, ERIKSEN E F, HOLMØY T. Multiple sclerosis，a cause of secondary osteoporosis? What is the evidence and what are the clinical implications?[J]. Acta Neurol Scand Suppl，2011(191)：44-49. DOI：10.1111/j.1600-0404.2011.01543.x.
[38]	GHAREGHANI M, SCAVO L, ARNOULT D, et al. Melatonin therapy reduces the risk of osteoporosis and normalizes bone formation in multiple sclerosis[J]. Fundam Clin Pharmacol，2018，32(2)：181-187. DOI：10.1111/fcp.12337.
[39]	BISSON E J, FINLAYSON M L, EKUMA O, et al. Multiple sclerosis is associated with low bone mineral density and osteoporosis[J]. Neurol Clin Pract，2019，9(5)：391-399. DOI：10.1212/CPJ.0000000000000669.
[40]	OLSSON A, OTURAI A B, SØNDERGAARD H B, et al. Bone microarchitecture and bone mineral density in multiple sclerosis[J]. Acta Neurol Scand，2018，137(3)：363-369. DOI：10.1111/ane.12884.
[41]	BISSON E J, FINLAYSON M L, EKUMA O, et al. Accuracy of FRAX® in people with multiple sclerosis[J]. J Bone Miner Res，2019，34(6)：1095-1100. DOI：10.1002/jbmr.3682.
[42]	SIMEAKIS G, ANAGNOSTOULI M, FAKAS N, et al. High-dose intravenous steroid treatment seems to have No long-term negative effect on bone mineral density of young and newly diagnosed multiple sclerosis patients：a pilot study[J]. Biomedicines，2023，11(2)：603. DOI：10.3390/biomedicines11020603.
[43]	ATKINSON S A, FLEET J C. Canadian recommendations for vitamin D intake for persons affected by multiple sclerosis[J]. J Steroid Biochem Mol Biol，2020，199：105606. DOI：10.1016/j.jsbmb.2020.105606.
[12]	李祥泽，卜宪敏，李冬梅，等. 创伤性脑外伤促进骨折愈合中的干细胞、细胞因子、激素、神经肽及基因[J]. 中国组织工程研究，2021，25(19)：3057-3063. DOI：10.3969/j.issn.2095-4344.2199.
[13]	KESAVAN C, RUNDLE C, MOHAN S. Repeated mild traumatic brain injury impairs fracture healing in male mice[J]. BMC Res Notes，2022，15(1)：25. DOI：10.1186/s13104-022-05906-7.
[14]	KESAVAN C, BAJWA N M, WATT H, et al. Growth hormone effects on bone loss-induced by mild traumatic brain injury and/or hind limb unloading[J]. Sci Rep，2019，9(1)：18995. DOI：10.1038/s41598-019-55258-9.
[15]	LEE J I, KIM J H, KIM H W, et al. Changes in bone metabolism in a rat model of traumatic brain injury[J]. Brain Inj，2005，19(14)：1207-1211. DOI：10.1080/02699050500309338.
[16]	LEE J H, CHO J H, LEE D G. Sclerostin concentration and bone biomarker trends in patients with spinal cord injury：a prospective study[J]. Healthcare，2022，10(6)：983. DOI：10.3390/healthcare10060983.
[17]	罗夕茗，王覃，许慎，等. 神经系统疾病相关骨质疏松症的发病机制与治疗[J]. 中华骨质疏松和骨矿盐疾病杂志，2017，10(1)：92-97. DOI：10.3969/j.issn.1674-2591.2017.01.016.
[18]	SHAMS R, DRASITES K P, ZAMAN V, et al. The pathophysiology of osteoporosis after spinal cord injury[J]. Int J Mol Sci，2021，22(6)：3057. DOI：10.3390/ijms22063057.
[19]	WU Y, WANG F, ZHANG Z. The efficacy and safety of bisphosphonate analogs for treatment of osteoporosis after spinal cord injury：a systematic review and meta-analysis of randomized controlled trials[J]. Osteoporos Int，2021，32(6)：1117-1127. DOI：10.1007/s00198-020-05807-0.
[20]	EDWARDS W B, SIMONIAN N, HAIDER I T, et al. Effects of teriparatide and vibration on bone mass and bone strength in people with bone loss and spinal cord injury：a randomized，controlled trial[J]. J Bone Miner Res，2018，33(10)：1729-1740. DOI：10.1002/jbmr.3525.
[21]	GIFRE L, VIDAL J, CARRASCO J L, et al. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury[J]. Osteoporos Int，2016，27(1)：405-410. DOI：10.1007/s00198-015-3333-5.
[44]	DUSCHA A, HEGELMAIER T, DÜRHOLZ K, et al. Propionic acid beneficially modifies osteoporosis biomarkers in patients with multiple sclerosis[J]. Ther Adv Neurol Disord，2022，15：17562864221103935. DOI：10.1177/17562864221103935.
[45]	XIE C X, WANG C L, LUO H. Increased risk of osteoporosis in patients with cognitive impairment：a systematic review and meta-analysis[J]. BMC Geriatr，2023，23(1)：797. DOI：10.1186/s12877-023-04548-z.
[46]	ZHAO Y, SHEN L, JI H F. Alzheimer's disease and risk of hip fracture：a meta-analysis study[J]. Sci World J，2012，2012：872173. DOI：10.1100/2012/872173.
[47]	CHEN Y H, LO R Y. Alzheimer's disease and osteoporosis[J]. Ci Ji Yi Xue Za Zhi，2017，29(3)：138-142. DOI：10.4103/tcmj.tcmj_54_17.
[48]	LLABRE J E, GIL C, AMATYA N, et al. Degradation of bone quality in a transgenic mouse model of Alzheimer's disease[J]. J Bone Miner Res，2022，37(12)：2548-2565. DOI：10.1002/jbmr.4723.
[49]	CUI S, XIONG F, HONG Y, et al. APPswe/Aβ regulation of osteoclast activation and RAGE expression in an age-dependent manner[J]. J Bone Miner Res，2011，26(5)：1084-1098. DOI：10.1002/jbmr.299.
[50]	LIU X X, CHEN C Y, JIANG Y L, et al. Brain-derived extracellular vesicles promote bone-fat imbalance in Alzheimer's disease[J]. Int J Biol Sci，2023，19(8)：2409-2427. DOI：10.7150/ijbs.79461.
[51]	DIMITRI P, ROSEN C. The central nervous system and bone metabolism：an evolving story[J]. Calcif Tissue Int，2017，100(5)：476-485. DOI：10.1007/s00223-016-0179-6.
[52]	FRIEDLAND R P, FRITSCH T, SMYTH K A, et al. Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members[J]. Proc Natl Acad Sci U S A，2001，98(6)：3440-3445. DOI：10.1073/pnas.061002998.
[53]	KUMAR S, CHANDNANI A, AUNG N H, et al. Alzheimer's disease and its association with bone health：a case-control study[J]. Cureus，2021，13(3)：e13772. DOI：10.7759/cureus.13772.
[54]	PU Z P, TANG X Q, FEI Y E, et al. Bone metabolic biomarkers and bone mineral density in male patients with early-stage Alzheimer's disease[J]. Eur Geriatr Med，2020，11(3)：403-408. DOI：10.1007/s41999-020-00289-z.
[55]	LUCKHAUS C, MAHABADI B, GRASS-KAPANKE B, et al. Blood biomarkers of osteoporosis in mild cognitive impairment and Alzheimer's disease[J]. J Neural Transm，2009，116(7)：905-911. DOI：10.1007/s00702-009-0241-x.
[56]	JIA R X, LIANG J H, XU Y, et al. Effects of physical activity and exercise on the cognitive function of patients with Alzheimer disease：a meta-analysis[J]. BMC Geriatr，2019，19(1)：181. DOI：10.1186/s12877-019-1175-2.
[57]	POWER R, PRADO-CABRERO A, MULCAHY R, et al. The role of nutrition for the aging population：implications for cognition and Alzheimer's disease[J]. Annu Rev Food Sci Technol，2019，10：619-639. DOI：10.1146/annurev-food-030216-030125.
[58]	MELO VAN LENT D, EGERT S, WOLFSGRUBER S, et al. Low serum vitamin D status is associated with incident Alzheimer's dementia in the oldest old[J]. Nutrients，2022，15(1)：61. DOI：10.3390/nu15010061.
[59]	ZULLO A R, ZHANG T T, LEE Y, et al. Effect of bisphosphonates on fracture outcomes among frail older adults[J]. J Am Geriatr Soc，2019，67(4)：768-776. DOI：10.1111/jgs.15725.
[60]	ZULLO A R, LEE Y, LARY C, et al. Comparative effectiveness of denosumab，teriparatide，and zoledronic acid among frail older adults：a retrospective cohort study[J]. Osteoporos Int，2021，32(3)：565-573. DOI：10.1007/s00198-020-05732-2.
[61]	YUAN J, PEDRINI S, THOTA R, et al. Elevated plasma sclerostin is associated with high brain amyloid-β load in cognitively normal older adults[J]. NPJ Aging，2023，9(1)：17. DOI：10.1038/s41514-023-00114-4.
[62]	VESTERGAARD KVIST A, FARUQUE J, VALLEJO-YAGÜE E, et al. Cardiovascular safety profile of romosozumab：a pharmacovigilance analysis of the US food and drug administration adverse event reporting system（FAERS）[J]. J Clin Med，2021，10(8)：1660. DOI：10.3390/jcm10081660.
[63]	ZAMEER S, ALI J, VOHORA D, et al. Development，optimisation and evaluation of chitosan nanoparticles of alendronate against Alzheimer's disease in intracerebroventricular streptozotocin model for brain delivery[J]. J Drug Target，2021，29(2)：199-216. DOI：10.1080/1061186X.2020.1817041.
[64]	JOSEPHSON C B, GONZALEZ-IZQUIERDO A, DENAXAS S, et al. Independent associations of incident epilepsy and enzyme-inducing and non-enzyme-inducing antiseizure medications with the development of osteoporosis[J]. JAMA Neurol，2023，80(8)：843-850. DOI：10.1001/jamaneurol.2023.1580.
[65]	BADDOO D R, MILLS A A, KULLAB R B, et al. Metabolic bone disease in patients with epilepsy and the use of antiepileptic drugs - Insight from a Danish cross-sectional study[J]. Seizure，2021，86：29-34. DOI：10.1016/j.seizure.2021.01.008.
[66]	SCHOUSBOE J T, BINKLEY N, LESLIE W D. Liver enzyme inducing anticonvulsant drug use is associated with prevalent vertebral fracture[J]. Osteoporos Int，2023，34(10)：1793-1798. DOI：10.1007/s00198-023-06820-9.
[67]	MIZIAK B, CHROŚCIŃSKA-KRAWCZYK M, CZUCZWAR S J. An update on the problem of osteoporosis in people with epilepsy taking antiepileptic drugs[J]. Expert Opin Drug Saf，2019，18(8)：679-689. DOI：10.1080/14740338.2019.1625887.
[68]	SINISCALCHI A, MURPHY S, CIONE E, et al. Antiepileptic drugs and bone health：current concepts[J]. Psychopharmacol Bull，2020，50(2)：36-44. DOI：10.1001/archneur.59.5.781.
[69]	SHARAWAT I K, DAWMAN L. Bone turnover analysis and vitamin D status in children with epilepsy[J]. Seizure，2019，73：83. DOI：10.1016/j.seizure.2019.07.013.
[70]	DIEMAR S S, SEJLING A S, EIKEN, et al. Effects of carbamazepine，eslicarbazepine，valproic acid and levetiracetam on bone microarchitecture in rats[J]. Pharmacol Rep，2020，72(5)：1323-1333. DOI：10.1007/s43440-020-00087-1.
[22]	FENG S H, HUANG Y P, YEH K C, et al. Osteoporosis and the risk of Parkinson's disease：a nationwide，propensity score-matched，longitudinal follow-up study[J]. J Clin Endocrinol Metab，2021，106(2)：e763-771. DOI：10.1210/clinem/dgaa864.
[23]	FIGUEROA C A, ROSEN C J. Parkinson's disease and osteoporosis：basic and clinical implications[J]. Expert Rev Endocrinol Metab，2020，15(3)：185-193. DOI：10.1080/17446651.2020.1756772.
[24]	METTA V, SANCHEZ T C, PADMAKUMAR C. Osteoporosis：a hidden nonmotor face of Parkinson's disease[J]. Int Rev Neurobiol，2017，134：877-890. DOI：10.1016/bs.irn.2017.05.034.
[71]	NISSEN-MEYER L S, SVALHEIM S, TAUBØLL E, et al. Levetiracetam，phenytoin，and valproate act differently on rat bone mass，structure，and metabolism[J]. Epilepsia，2007，48(10)：1850-1860. DOI：10.1111/j.1528-1167.2007.01176.x.
[72]	SEENS H, MODARRESI S, MACDERMID J C, et al. Prevalence of bone fractures among children and adolescents with attention-deficit/hyperactivity disorder：a systematic review and meta-analysis[J]. BMC Pediatr，2021，21(1)：354. DOI：10.1186/s12887-021-02821-x.
[73]	PAZOS-PÉREZ A, PIÑEIRO-RAMIL M, FRANCO-TREPAT E, et al. Methylphenidate promotes premature growth plate closure：in vitro evidence[J]. Int J Mol Sci，2023，24(4)：4175. DOI：10.3390/ijms24044175.
[74]	UDDIN S M Z, ROBISON L S, FRICKE D, et al. Methylphenidate regulation of osteoclasts in a dose- and sex-dependent manner adversely affects skeletal mechanical integrity[J]. Sci Rep，2018，8(1)：1515. DOI：10.1038/s41598-018-19894-x.
[75]	CHIROKIKH A A, UDDIN S M Z, AREIKAT N, et al. Combined methylphenidate and fluoxetine treatment in adolescent rats significantly impairs weight gain with minimal effects on skeletal development[J]. Bone，2023，167：116637. DOI：10.1016/j.bone.2022.116637.
[76]	XU J, YU L X, LIU F, et al. The effect of cytokines on osteoblasts and osteoclasts in bone remodeling in osteoporosis：a review[J]. Front Immunol，2023，14：1222129. DOI：10.3389/fimmu.2023.1222129.
[77]	D'AMELIO P, GRIMALDI A, BERNABEI P, et al. Immune system and bone metabolism：does thymectomy influence postmenopausal bone loss in humans?[J]. Bone，2006，39(3)：658-665. DOI：10.1016/j.bone.2006.03.009.
[78]	LV F, GUAN Y Z, MA D D, et al. Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment[J]. Clin Endocrinol，2018，88(3)：380-387. DOI：10.1111/cen.13537.
[79]	KESIKBURUN S, GÜZELKÜÇÜK U, ALAY S, et al. Exacerbation of myasthenia gravis by alendronate[J]. Osteoporos Int，2014，25(9)：2319-2320. DOI：10.1007/s00198-014-2768-4.
[80]	ROSSINI M, ADAMI S, VIAPIANA O, et al. Acute phase response after zoledronic acid is associated with long-term effects on white blood cells[J]. Calcif Tissue Int，2013，93(3)：249-252. DOI：10.1007/s00223-013-9750-6.
[81]	KANEKO J, OKINAGA T, HIKIJI H, et al. Zoledronic acid exacerbates inflammation through M1 macrophage polarization[J]. Inflamm Regen，2018，38：16. DOI：10.1186/s41232-018-0074-9.
[82]	ODAME I, DUCKWORTH J, TALSMA D, et al. Osteopenia，physical activity and health-related quality of life in survivors of brain tumors treated in childhood[J]. Pediatr Blood Cancer，2006，46(3)：357-362. DOI：10.1002/pbc.20512.
[83]	KANG M J, KIM S M, LEE Y A, et al. Risk factors for osteoporosis in long-term survivors of intracranial germ cell tumors[J]. Osteoporos Int，2012，23(7)：1921-1929. DOI：10.1007/s00198-011-1821-9.
[84]	BOSCO F, GUARNIERI L, NUCERA S, et al. Pathophysiological aspects of muscle atrophy and osteopenia induced by chronic constriction injury（CCI）of the sciatic nerve in rats[J]. Int J Mol Sci，2023，24(4)：3765. DOI：10.3390/ijms24043765.
[85]	SHIMADA N, SAKATA A, IGARASHI T, et al. M1 macrophage infiltration exacerbate muscle/bone atrophy after peripheral nerve injury[J]. BMC Musculoskelet Disord，2020，21(1)：44. DOI：10.1186/s12891-020-3069-z.

神经系统疾病及相关治疗药物对骨质疏松症影响的研究进展

Research Progress on the Influence of Nervous System Diseases and Related Therapeutic Drugs on Osteoporosis

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 85

相关文章 15

编辑推荐

Metrics

留言

[1]	朱子一, 何贵新, 秦伟彬, 宋惠, 张利文, 唐伟智, 杨斐斐, 刘凌云, 欧阳彬. 线粒体自噬改善心肌梗死后心肌纤维化及其中医药干预的研究进展[J]. 中国全科医学, 2025, 28(18): 2294-2300.
[2]	褚田雨, 顾艳. 颈动脉钙化特征在评估斑块稳定性及临床事件中的作用[J]. 中国全科医学, 2025, 28(18): 2247-2252.
[3]	陈钡钡, 李佳, 谭文彬. 内分泌代谢系统疾病与继发性骨质疏松症的研究新进展[J]. 中国全科医学, 2025, 28(17): 2082-2091.
[4]	曹沁涵, 卓肖, 夏雨菡, 车杨曦, 陈敏. 2024年V1/V2版《NCCN直肠癌临床实践指南》更新要点解读[J]. 中国全科医学, 2025, 28(17): 2070-2074.
[5]	贺婷, 李佳, 谭文彬. 循环系统疾病与继发性骨质疏松症的研究新进展[J]. 中国全科医学, 2025, 28(17): 2101-2112.
[6]	李佳, 谭文彬. 继发性骨质疏松症防治困境与对策探究[J]. 中国全科医学, 2025, 28(17): 2075-2081.
[7]	顾洁, 黄延焱. 罕见病诊治及全过程管理：全科医生的作用不可或缺[J]. 中国全科医学, 2025, 28(16): 1955-1960.
[8]	隋鸿平, 李婷婷, 姜桐桐, 夏云龙, 史铁英. 血管内皮生长因子信号通路抑制剂相关高血压的血压管理研究进展[J]. 中国全科医学, 2025, 28(15): 1932-1936.
[9]	邓毅凡, 何胜虎, 张晶, 朱莉. 钠-葡萄糖共转运蛋白2抑制剂对急性心肌梗死患者经皮冠状动脉介入治疗术后主要不良心血管事件发生的影响：一项Meta分析[J]. 中国全科医学, 2025, 28(15): 1884-1890.
[10]	孙沁瑜, 邓毅凡, 何胜虎, 张晶. 中性粒细胞/淋巴细胞比值、单核细胞/高密度脂蛋白胆固醇比值及两者联合对急性ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗术后造影剂肾病的预测价值研究[J]. 中国全科医学, 2025, 28(15): 1891-1897.
[11]	曹干, 邓毅凡, 何胜虎, 张晶. 乳酸脱氢酶与白蛋白比值与急性ST段抬高型心肌梗死急诊经皮冠状动脉介入治疗术后患者预后的相关性研究[J]. 中国全科医学, 2025, 28(15): 1878-1883.
[12]	马桂芬, 章倩, 孙菁. 2024年《NCCN胃癌临床实践指南》更新要点解读[J]. 中国全科医学, 2025, 28(14): 1681-1688.
[13]	宋洪娜, 许洪梅, 刘玉环, 王青龙, 汤云昭, 于翔. 冠心病合并糖尿病患者经皮冠状动脉介入治疗术后共病随访模式的构建及应用效果研究[J]. 中国全科医学, 2025, 28(14): 1737-1743.
[14]	李伊婷, 徒文静, 尹婷婷, 梅紫琦, 张苏闽, 王萌, 徐桂华. 人工智能在炎症性肠病患者营养管理中应用的范围综述[J]. 中国全科医学, 2025, 28(14): 1709-1716.
[15]	朱胜杰, 刁华琼, 杭晓屹, 孙文军. 不同中成药注射液治疗后循环缺血性眩晕效果的网状Meta分析[J]. 中国全科医学, 2025, 28(14): 1795-1808.